24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
10:39
Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff
10:29
Intel VP: “We had 11 or 12 layers of management... now it’s 5 or 6”
21:48
From textile recycling to autonomous vessels: The vision behind the Dream Team startups
20:25
ELNET: German business leaders “are looking with admiration and respect towards the Startup Nation”
More stories
Buzz
Most popular
Daily
Weekly
1
Check Point raises $1.75 billion, potentially eyeing AI expansion
2
Inside the mind of a Nobel physicist: John Martinis on the future of quantum computing
3
Hapag-Lloyd eyes ZIM acquisition, workers push back
4
Cybereason founders' 7AI raises record $130 million Series A in breakneck rise
5
Nice puts Actimize up for sale at a $1.5-2 billion price tag
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026